- Home
- REE vs APM Comparison
REE vs APM Comparison
Compare REE & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- APM
- Stock Information
- Founded
- REE 2011
- APM 2010
- Country
- REE Israel
- APM United Kingdom
- Employees
- REE N/A
- APM N/A
- Industry
- REE Auto Manufacturing
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- APM Health Care
- Exchange
- REE Nasdaq
- APM Nasdaq
- Market Cap
- REE 18.5M
- APM 18.9M
- IPO Year
- REE N/A
- APM 2018
- Fundamental
- Price
- REE $0.67
- APM $1.85
- Analyst Decision
- REE Strong Buy
- APM
- Analyst Count
- REE 2
- APM 0
- Target Price
- REE $11.75
- APM N/A
- AVG Volume (30 Days)
- REE 60.3K
- APM 20.3M
- Earning Date
- REE 09-25-2025
- APM 04-30-2025
- Dividend Yield
- REE N/A
- APM N/A
- EPS Growth
- REE N/A
- APM N/A
- EPS
- REE N/A
- APM N/A
- Revenue
- REE $183,000.00
- APM N/A
- Revenue This Year
- REE $6,661.20
- APM N/A
- Revenue Next Year
- REE $2,240.01
- APM N/A
- P/E Ratio
- REE N/A
- APM N/A
- Revenue Growth
- REE N/A
- APM N/A
- 52 Week Low
- REE $0.53
- APM $0.46
- 52 Week High
- REE $11.72
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- REE 42.94
- APM 50.26
- Support Level
- REE $0.64
- APM $1.64
- Resistance Level
- REE $0.77
- APM $1.90
- Average True Range (ATR)
- REE 0.04
- APM 0.36
- MACD
- REE -0.00
- APM -0.06
- Stochastic Oscillator
- REE 22.50
- APM 18.38
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.